- Home
- AKBA vs ASA Comparison
AKBA vs ASA Comparison
Compare AKBA & ASA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- ASA
- Stock Information
- Founded
- AKBA 2007
- ASA 1958
- Country
- AKBA United States
- ASA United States
- Employees
- AKBA N/A
- ASA N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- ASA Precious Metals
- Sector
- AKBA Health Care
- ASA Industrials
- Exchange
- AKBA Nasdaq
- ASA Nasdaq
- Market Cap
- AKBA 669.7M
- ASA 549.0M
- IPO Year
- AKBA 2014
- ASA N/A
- Fundamental
- Price
- AKBA $3.69
- ASA $34.47
- Analyst Decision
- AKBA Strong Buy
- ASA
- Analyst Count
- AKBA 5
- ASA 0
- Target Price
- AKBA $6.90
- ASA N/A
- AVG Volume (30 Days)
- AKBA 6.0M
- ASA 56.2K
- Earning Date
- AKBA 05-08-2025
- ASA 06-17-2025
- Dividend Yield
- AKBA N/A
- ASA 0.14%
- EPS Growth
- AKBA N/A
- ASA N/A
- EPS
- AKBA N/A
- ASA 11.67
- Revenue
- AKBA $184,909,000.00
- ASA $3,557,386.00
- Revenue This Year
- AKBA $23.32
- ASA N/A
- Revenue Next Year
- AKBA $49.90
- ASA N/A
- P/E Ratio
- AKBA N/A
- ASA $2.92
- Revenue Growth
- AKBA N/A
- ASA 45.39
- 52 Week Low
- AKBA $0.80
- ASA $16.97
- 52 Week High
- AKBA $3.73
- ASA $35.00
- Technical
- Relative Strength Index (RSI)
- AKBA 83.69
- ASA 72.50
- Support Level
- AKBA $2.76
- ASA $31.24
- Resistance Level
- AKBA $3.73
- ASA $34.19
- Average True Range (ATR)
- AKBA 0.18
- ASA 0.90
- MACD
- AKBA 0.07
- ASA 0.41
- Stochastic Oscillator
- AKBA 96.67
- ASA 92.37
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.